AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sodium-dependent serotonin transporter

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P31645

UPID:

SC6A4_HUMAN

Alternative names:

5HT transporter; Solute carrier family 6 member 4

Alternative UPACC:

P31645; Q5EE02

Background:

The Sodium-dependent serotonin transporter, also known as 5HT transporter or Solute carrier family 6 member 4, plays a pivotal role in serotonin homeostasis. It transports serotonin across the plasma membrane, limiting its intercellular signaling. This protein is essential in the central nervous system for serotonin uptake, influencing the spatial organization of cortical neurons and the elaboration of sensory circuits. Additionally, it modulates serotonin levels in the gastrointestinal tract and regulates blood serotonin levels, crucial for enteric neurogenesis and gastrointestinal reflexes.

Therapeutic significance:

Understanding the role of the Sodium-dependent serotonin transporter could open doors to potential therapeutic strategies. Its critical function in serotonin homeostasis and signaling termination at synapses highlights its potential as a target for treating disorders related to serotonin imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.